Bristol-Myers Squibb (BMY) Misses Q4 EPS by 4c; Guides Below the Street

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. AXP
9. ZETA
10. DAL

Go back to Bristol-Myers Squibb (BMY) Misses Q4 EPS by 4c; Guides Below the Street

Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results

January 26, 2017 6:59 AM EST

Increases Fourth Quarter Revenues 22% to $5.2 Billion, 17% for Full Year to $19.4 Billion Posts Fourth Quarter GAAP EPS of $0.53 and Non-GAAP EPS of $0.63 Announces Settlement and License Agreement to Resolve PD-1 Patent Litigation Against Merck Achieves Important Regulatory Milestones for Opdivo Approved in the U.S. for Metastatic Squamous Cell Carcinoma of the Head and Neck Approved in Europe for Classical Hodgkin Lymphoma Completes Strategic Transactions in Oncology and Fibrosis... More